228 Participants Needed

Gamified Weight Loss Program for Obesity

(DASH-Man Trial)

MC
EM
EF
Overseen ByEvan Forman, Ph.D
Age: 18 - 65
Sex: Any
Trial Phase: Academic
Sponsor: Drexel University
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

Men in the United States have an exceptionally high prevalence of overweight and obesity, i.e., 71.3%, and 42% of men are currently attempting weight loss. However, men are dramatically underrepresented in weight loss programs. Attempts to modestly adapt standard weight loss programs have seen only minimal success. Mobile applications (mHealth apps) have attractive features, but have low male enrollment and poor efficacy as conventionally delivered. A gamified mHealth program offers the possibility of engaging men and enhancing efficacy given that (1) video gaming is highly appealing to men; (2) gamification features (e.g., digital rewards for attaining "streaks" and milestones, competition) are known enhance enjoyment and motivation and facilitate desired behaviors; and (3) "neurotraining" video games featuring repetitive action mechanics, adaptive difficulty, and feedback can train inhibitory control, a basic brain capacity to inhibit intrinsically-generated approach responses that is strongly linked to body mass and the consumption of high-calorie foods. This project evaluates long-term engagement and outcomes of a professionally-designed, game-based weight loss program. As such, 228 overweight men will be randomized to: (1) a 12-month mHealth weight loss program that includes digital self-monitoring, simplified and self-selected dietary targets, physical activity and a control (sham) non-game neurotraining, or (2) a fully-gamified version of this same program, comprised of a behavior change program featuring team-based competition, digital reinforcers for attainment of streaks and milestones, and an integrated neurotraining video game. Aims include evaluating the efficacy of the gamified program in terms of weight loss, diet and physical activity at 12 months, as well as evaluating hypothesized mediators (inhibitory control and engagement), (enjoyment and compliance) and moderators (baseline frequency of video game play and implicit preferences for Inhibitory Control Training-targeted foods).

Will I have to stop taking my current medications?

The trial does not specify if you need to stop taking your current medications. However, if you have recently started or changed the dosage of a medication that can significantly affect your weight, you may not be eligible to participate.

Is the gamified weight loss program safe for humans?

The available research on gamified weight loss programs, such as the SIGMA app, primarily focuses on their design and potential effectiveness rather than safety. However, these programs are based on cognitive behavior therapy principles, which are generally considered safe for most people.12345

What makes the Gamified Weight Loss Program for Obesity unique compared to other treatments?

The Gamified Weight Loss Program is unique because it combines cognitive behavior therapy (CBT) principles with a mobile app designed as a game, allowing users to earn points for both in-app activities and real-world physical activities. This approach makes weight loss more engaging and accessible, especially for young adults with maladaptive eating habits, by using a novel scoring system and gamification to encourage behavior change.12356

What data supports the effectiveness of the Gamified Weight Loss Program for Obesity treatment?

Research shows that gamified and digital interventions, like the SIGMA app, which use cognitive behavior therapy (CBT) principles, can help with weight loss by addressing unhealthy eating habits. Additionally, studies indicate that using behavior change techniques and incentives in digital programs can lead to weight loss, suggesting that similar gamified approaches may be effective.12578

Are You a Good Fit for This Trial?

This trial is for overweight or obese men (BMI of 25-50 kg/m²) aged 18-65 who enjoy high-calorie foods and can walk two city blocks without stopping. They must be willing to have their doctor contacted about their physical activity level and rapid weight loss if needed. Men with certain medical conditions, recent significant weight loss, or changes in medications affecting weight are excluded.

Inclusion Criteria

My BMI is between 25 and 50, indicating I am overweight or obese.
Satisfactory completion of all enrollment procedures
Individuals must also provide consent for the research team to contact their personal physician, if necessary, to provide clearance for the prescribed level of physical activity (i.e., walking) or to consult about rapid weight loss
See 2 more

Exclusion Criteria

I have lost 5% or more of my weight in the last 3 months.
I recently started or changed the dose of a medication that may significantly affect my weight.
I have had weight loss surgery in the past.
See 1 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants engage in a 12-month mHealth weight loss program with digital self-monitoring, dietary targets, and physical activity, with either a sham or active neurotraining component.

12 months

Follow-up

Participants are monitored for weight loss, diet, and physical activity outcomes, with assessments at months 0, 1, 6, and 12.

12 months

What Are the Treatments Tested in This Trial?

Interventions

  • Gamified behavioral weight loss treatment
  • mHealth behavioral weight loss treatment
Trial Overview The study tests a gamified mHealth program against a standard mHealth program for weight loss in men. It includes digital self-monitoring, dietary targets, physical activity, and either a control neurotraining game or an integrated one with team competition and rewards designed to train inhibitory control linked to body mass.
How Is the Trial Designed?
4Treatment groups
Experimental Treatment
Active Control
Placebo Group
Group I: Gamified program with sham ICTExperimental Treatment1 Intervention
Group II: Gamified program with Active ICTExperimental Treatment1 Intervention
Group III: Non-gamified program with Active ICTActive Control1 Intervention
Group IV: Non-gamified program with sham ICTPlacebo Group1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

Drexel University

Lead Sponsor

Trials
160
Recruited
48,600+

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Collaborator

Trials
2,513
Recruited
4,366,000+

Published Research Related to This Trial

The SIGMA mobile app, based on cognitive behavior therapy principles, aims to help overweight young adults with maladaptive eating habits by gamifying self-help strategies, making it a potentially accessible alternative to traditional in-person therapy.
The intervention will be tested in a randomized, placebo-controlled trial over 2 months, focusing on changes in maladaptive thoughts and eating behaviors, with follow-up on weight and physical activity, highlighting its potential as a cost-effective tool for weight management.
An evidence-based gamified mHealth intervention for overweight young adults with maladaptive eating habits: study protocol for a randomized controlled trial.Podina, IR., Fodor, LA., Cosmoiu, A., et al.[2019]
This study is testing a 24-week weight loss intervention for individuals with obesity, using a smartphone app for dietary self-monitoring and daily weight tracking, combined with financial incentives for meeting weight loss goals.
The pilot study aims to assess the feasibility of real-time financial rewards to improve adherence and retention in weight loss programs, potentially leading to effective long-term weight management strategies.
Study protocol for Log2Lose: A feasibility randomized controlled trial to evaluate financial incentives for dietary self-monitoring and interim weight loss in adults with obesity.Voils, CI., Levine, E., Gierisch, JM., et al.[2019]
Automated digital interventions for weight loss showed a small but significant average weight loss of -1.37 kg compared to control groups, based on a systematic review of 66 trials involving 13,672 participants.
The most effective interventions utilized behavior change techniques (BCTs) such as goal-setting and feedback, with social incentive/reward techniques linked to greater weight loss efficacy, although these findings require further validation.
Associations between behaviour change technique clusters and weight loss outcomes of automated digital interventions: a systematic review and meta-regression.Berry, MP., Chwyl, C., Metzler, AL., et al.[2023]

Citations

An evidence-based gamified mHealth intervention for overweight young adults with maladaptive eating habits: study protocol for a randomized controlled trial. [2019]
Study protocol for Log2Lose: A feasibility randomized controlled trial to evaluate financial incentives for dietary self-monitoring and interim weight loss in adults with obesity. [2019]
Associations between behaviour change technique clusters and weight loss outcomes of automated digital interventions: a systematic review and meta-regression. [2023]
Using artificial intelligence to optimize delivery of weight loss treatment: Protocol for an efficacy and cost-effectiveness trial. [2023]
BestFIT Sequential Multiple Assignment Randomized Trial Results: A SMART Approach to Developing Individualized Weight Loss Treatment Sequences. [2022]
A smartphone-supported weight loss program: design of the ENGAGED randomized controlled trial. [2021]
Review of innovations in digital health technology to promote weight control. [2021]
Perceived helpfulness of the individual components of a behavioural weight loss program: results from the Hopkins POWER Trial. [2021]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security